BELLUS Health Inc.
https://bellushealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BELLUS Health Inc.
Glenmark Chief On ‘Big Shift’ In Revenue By Region, Liraglutide India Outlook
Momentum in Europe may see the region’s contribution to Glenmark’s revenues become almost as big as the US business, currently dented by multiple challenges. The firm also outlines how things are poised in India for its biosimilar to Novo Nordisk’s Victoza.
Finance Watch: Actuate Launches 15th Biopharma IPO In The US For 2024
Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.
Rejuvenated A Year Into Saunders’ Return To Helm, B+L Refreshing Blink, Lumify Lines
Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.
Finance Watch: VC Mega-Rounds Ease Into Summer Slowdown
Private Company Edition: Venture capital investment has moved into a slower summer pace, or maybe just shifted to small- and medium-sized biopharma financings. In addition to Third Arc’s $165m series A round, Brenig raised a $65m series A and Confo’s series B totaled €60m ($65m).
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Neurochem
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice